The FDA has become the latest organization to validate the potential of Vor Biopharma’s approach to CRISPR-powered cell engineering, granting fast-track status to its lead asset shortly after Johnson ...
(RTTNews) - Vor Biopharma (VOR), a clinical-stage cell and genome engineering company, announced that its VOR33 was granted Fast Track designation by the U.S. Food and Drug Administration. VOR33 is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback